These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 12880690)

  • 1. Pre-diabetes, insulin resistance, inflammation and CVD risk.
    Haffner SM
    Diabetes Res Clin Pract; 2003 Jul; 61 Suppl 1():S9-S18. PubMed ID: 12880690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C-reactive protein, its role in inflammation, Type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones.
    Nesto R
    Diabet Med; 2004 Aug; 21(8):810-7. PubMed ID: 15270782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin resistance, inflammation, and the prediabetic state.
    Haffner SM
    Am J Cardiol; 2003 Aug; 92(4A):18J-26J. PubMed ID: 12957323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of rosiglitazone and aspirin on experimental model of induced type 2 diabetes in rats: focus on insulin resistance and inflammatory markers.
    Abdin AA; Baalash AA; Hamooda HE
    J Diabetes Complications; 2010; 24(3):168-78. PubMed ID: 19328014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type 2 diabetes, cardiovascular risk, and the link to insulin resistance.
    Stolar MW; Chilton RJ
    Clin Ther; 2003; 25 Suppl B():B4-31. PubMed ID: 14553864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
    Chu CS; Lee KT; Lee MY; Su HM; Voon WC; Sheu SH; Lai WT
    Am J Cardiol; 2006 Mar; 97(5):646-50. PubMed ID: 16490430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
    Haffner SM; Greenberg AS; Weston WM; Chen H; Williams K; Freed MI
    Circulation; 2002 Aug; 106(6):679-84. PubMed ID: 12163427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
    Hemmingsen B; Lund SS; Vaag A
    Ugeskr Laeger; 2009 May; 171(19):1598-602. PubMed ID: 19419642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammation and the etiology of type 2 diabetes.
    Sjöholm A; Nyström T
    Diabetes Metab Res Rev; 2006; 22(1):4-10. PubMed ID: 15991254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of rosiglitazone on inflammatory reaction and insulin resistance in obese patients with newly diagnosed type 2 diabetes].
    Zhu HL; Yu RM; Huang XZ; Huang W
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Jun; 28(6):1050-1. PubMed ID: 18583261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion.
    Festa A; Hanley AJ; Tracy RP; D'Agostino R; Haffner SM
    Circulation; 2003 Oct; 108(15):1822-30. PubMed ID: 14517163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interrelationships between inflammation, C-reactive protein, and insulin resistance.
    Ndumele CE; Pradhan AD; Ridker PM
    J Cardiometab Syndr; 2006; 1(3):190-6. PubMed ID: 17679826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of the thiazolidinediones in the practical management of patients with type 2 diabetes and cardiovascular risk factors.
    Edelman SV
    Rev Cardiovasc Med; 2003; 4 Suppl 6():S29-37. PubMed ID: 14668701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans.
    Wang Y; Lam KS; Kraegen EW; Sweeney G; Zhang J; Tso AW; Chow WS; Wat NM; Xu JY; Hoo RL; Xu A
    Clin Chem; 2007 Jan; 53(1):34-41. PubMed ID: 17040956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PCOS and diabetes mellitus: from insulin resistance to altered beta pancreatic function, a link in evolution.
    Condorelli RA; Calogero AE; Di Mauro M; La Vignera S
    Gynecol Endocrinol; 2017 Sep; 33(9):665-667. PubMed ID: 28644709
    [No Abstract]   [Full Text] [Related]  

  • 16. Diabetes and cardiovascular risk markers.
    Erdmann E
    Curr Med Res Opin; 2005; 21 Suppl 1():S21-8. PubMed ID: 15811196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Profile of the Immune and Inflammatory Response in Individuals With Prediabetes and Type 2 Diabetes.
    Grossmann V; Schmitt VH; Zeller T; Panova-Noeva M; Schulz A; Laubert-Reh D; Juenger C; Schnabel RB; Abt TG; Laskowski R; Wiltink J; Schulz E; Blankenberg S; Lackner KJ; Münzel T; Wild PS
    Diabetes Care; 2015 Jul; 38(7):1356-64. PubMed ID: 25877811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease.
    Haffner SM
    Am J Cardiol; 2006 Jan; 97(2A):3A-11A. PubMed ID: 16442931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers.
    Mudaliar S; Henry RR
    Annu Rev Med; 2001; 52():239-57. PubMed ID: 11160777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pioglitazone administration decreases cardiovascular disease risk factors in insulin-resistant smokers.
    Abbasi F; Farin HM; Lamendola C; McGraw L; McLaughlin T; Reaven GM
    Metabolism; 2008 Aug; 57(8):1108-14. PubMed ID: 18640389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.